Table 4.
Development of antibodies to PCV2 in serum of pigs experimentally infected with PCV2-1010 and PPV (no. 3) or S-PCV2 and PPV in Sweden (no. 4) or Denmark (no. 5)
| PCV2-1010 + PPV (no. 3 Swe) |
S-PCV2 + PPV (no. 4 Swe) |
S-PCV2 + PPV (no. 5 Den) |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pig | Days post infection |
Pig | Days post infection |
Pig | Days post infection |
|||||||||||||
| 0 | 8 | 15 | 22 | 28 | 0 | 8 | 15 | 22 | 28 | 0 | 4 | 7 | 14 | 21 | 27 | |||
| A7 | < | < | < | 1600 | 6400 | A3 | < | < | < | 50 | < | 1 | < | < | < | < | 250 | >6250 |
| B1 | < | < | < | 1600 | 12500 | B7 | < | < | 100 | 200 | 200 | 2 | < | < | < | 50 | Dead | Dead |
| B6 | < | < | 200 | 3200 | 1600 | B8 | < | < | 100 | 100 | 100 | 3 | < | < | < | 250 | 1250 | >6250 |
| B11 | < | < | 50 | 1600 | 1600 | C3 | < | < | 50 | 3200 | 50000 | 4 | < | < | < | Dead | Dead | Dead |
| B14 | < | < | 50 | 6400 | 25000 | D3 | < | < | < | Dead | Dead | 5 | < | < | < | 250 | 250 | 250 |
| C1 | < | < | < | 800 | 12500 | D9 | < | < | < | < | Dead | 6 | < | < | < | < | 50 | 250 |
| D1 | < | < | 200 | 3200 | 6400 | E3 | < | < | < | 50 | < | 7 | < | < | < | 250 | 50 | 50 |
| D2 | < | < | 100 | 200 | Dead | – | – | – | – | – | – | 8 | < | < | < | 250 | Dead | Dead |
| D8 | < | < | 400 | 12500 | Dead | – | – | – | – | – | – | – | – | – | – | – | – | – |
| E5 | < | < | NT | 50 | 6400 | – | – | – | – | – | – | – | – | – | – | – | – | – |
The serum levels of antibodies are given as reciprocal titers, determined in an immunoperoxidase monolayer assay.